AI Article Synopsis
- Scientists are using special tests called biomarkers to help treat cancer patients, especially those with lung cancer.
- In one case, a patient had a rare type of lung cancer, and advanced tests found unusual changes in their genes.
- The results from these tests helped the doctors decide the best treatment for the patient, showing how important it is to understand the details of each person's cancer.
Article Abstract
Introduction: Several biomarkers are currently available to address targeted treatments in cancer patients, with lung malignancies representing one of the best examples.
Case Description: We report the case of a patient affected by advanced non-small cell lung cancer with an uncommon histology and a complex biology. The use of a large next-generation sequencing (NGS) NGS panel allowed us to identify an extremely rare mutation (V600Q), a amplification, a high tumor mutational burden, a germline pathogenetic mutation and a homologous recombination deficiency through RAD51 assay. The treatment decision was driven by the abundance of molecular information.
Conclusions: This case highlights that an attentive and critical evaluation of molecular reports is key for the tailoring of treatment algorithms at the patient-level scale.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03008916241257754 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!